| AC220-007 | A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) Consolidation | Open |
| CALGB10403 | An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) | Open (affiliates only) |
| CALGB10503 | Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years | Open (affiliates only) |
| CALGB10603 | A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) | Open (affiliates only) |
| CALGB50403 | A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma | Open (affiliates only) |
| COGAAML1031 | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | Open |
| E1910 | A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults. | Open |
| LCCC1522 | Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia | Open |